Inotek’s treatment for glaucoma misses main goal in late-stage study

(Reuters) – Inotek Pharmaceuticals Corp said on Tuesday that its treatment for glaucoma did not meet its main goal in the first pivotal late-stage study.

The company said the main goal of superiority was not achieved over a placebo.

(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel)